NCT02229929已完成2 期
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Pharmacokinetics of Intravenous CR845 in Hemodialysis Patients, and Its Safety and Efficacy in Hemodialysis Patients With Uremic Pruritus
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 89
- 试验地点
- 20
- 主要终点
- Part B: Change in Worst Itching Intensity using a 100-mm Visual Analog Scale
研究概览
简要总结
The primary purpose of this study is to:
- Evaluate the safety and pharmacokinetic profile of repeated doses IV CR845 over one week in patients who are undergoing hemodialysis. (Part A)
- This study is also investigating whether repeated doses of IV CR845 over two weeks is safe and effective in reducing the intensity of itching in hemodialysis patients with uremic pruritus (Part B).
详细描述
Placebo-controlled
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able to provide written informed consent prior to any study procedures;
- •Able to communicate clearly with the Investigator and staff, able to read and understand the study procedures;
- •Males or females 18 years of age or older;
- •End stage renal disease (ESRD) patients who have been on hemodialysis for at least three months and are currently on hemodialysis:
- •At least three times per week (Part A)
- •Three times per week (Part B)
- •Has a body weight ≤ 135 kg
- •Part B: Patient who self-reports daily or near daily pruritus during the 6 weeks prior to Screening;
- •Part B: Patient who reports a Patient B or Patient C profile on the Patient Self-categorization of Pruritus Disease Severity questionnaire at Screening;
- •Part B: At the end of the Run-in Period:
- •Patient who completed ratings of worst itching intensity [visual analog scale (VAS)] at least 8 times out of 14 VAS assessments;
- •Patient who has a mean value of >40 mm on the worst itching VAS over the one week Run-in Period.
排除标准
- •Known to be non-compliant with dialysis treatment (i.e., has a history of missed dialysis sessions due to non-compliance in the past 2 months);
- •Anticipated to receive a kidney transplant during the study;
- •Known history of allergic reaction to opiates such as hives (Note: side effects related to the use of opioids such as constipation or nausea would not exclude the patients from the study);
- •Known or suspected history of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)-diagnosed alcohol, narcotic, or other drug abuse or dependence within 12 months prior to Screening;
- •Acute or unstable medical condition(s) such as congestive heart failure [New York Heart Association (NYHA) class IV], which in the opinion of the Investigator would pose undue risk to the patient or would impede complete collection of the data or its evaluability;
- •Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) greater than 2.5X the reference upper limit of normal (ULN), or bilirubin greater than 4X the ULN at Screening;
- •Received another investigational drug within 30 days prior to the start of the Run-in Period or has planned to participate in another clinical trial while enrolled in this study
- •Part B: Has pruritus probably or definitely attributed to a cause other than ESRD or its complications (e.g., patients with concomitant pruritic dermatological disease or cholestatic liver disease would be excluded). (Note: Patients whose pruritus is attributed to ESRD complications such as hyperparathyroidism, hyperphosphatemia, anemia, or the dialysis procedure or prescription may be enrolled);
- •Part B: Has localized itch restricted to the palms of the hands as determined from the Brief Itch Inventory diagram, completed during the Screening Period;
- •Part B: Has pruritus only during the dialysis session (by patient report);
- •Part B: Has used gabapentin, calcineurin inhibitors, opioids; antipsychotics; systemic or topical corticosteroids (other than otic or ophthalmic preparations); sedatives; hypnotics; anti-anxiety agents selective serotonin reuptake inhibitors (SSRIs); or tricyclic antidepressants for < 4 weeks prior to the start of the Run-In Period or had a dose change within the previous 30 days;
- •Part B: Is not willing to abstain from use of antihistamines (oral, IV, or topical) for 3 weeks (from the start of the Run-In Period through the end of Week 2);
- •Part B: Not willing to abstain from making changes to topical non-drug treatments (e.g., emollients, creams, oils) for pruritus for 3 weeks (from the start of the Run-In Period through the end of Week 2);
- •Part B: Received ultraviolet B treatment within 30 days prior to the start of the Run-in Period.
研究组 & 干预措施
Part A: Placebo
Placebo Comparator
Intravenous matched placebo
干预措施: Part A: Placebo (Drug)
Part A: CR845 0.5 mcg/kg
Experimental
Intravenous CR845, 0.5 mcg/kg
干预措施: Part A: CR845 0.5 mcg/kg (Drug)
Part A: CR845 1.0 mcg/kg
Experimental
Intravenous CR845, 1.0 mcg/kg
干预措施: Part A: CR845 1.0 mcg/kg (Drug)
Part A: CR845 2.5 mcg/kg
Experimental
Intravenous CR845, 2.5 mcg/kg
干预措施: Part A: CR845 2.5 mcg/kg (Drug)
Part B: Placebo
Placebo Comparator
Intravenous matched placebo
干预措施: Part B: Placebo (Drug)
Part B: CR845 1.0 mcg/kg
Experimental
Intravenous CR845, 1.0 mcg/kg
干预措施: Part B: CR845 1.0 mcg/kg (Drug)
结局指标
主要结局
Part B: Change in Worst Itching Intensity using a 100-mm Visual Analog Scale
时间窗: 2 weeks
Change from baseline to the average of Week 2 worst itching (daytime and nighttime) VAS where 0 mm represents "No Itch" and 100 mm represents the "Worst Itch You Can Imagine".
Part A: Determine the Pharmacokinetics of Repeated Doses of CR845 in Hemodialysis Patients (half-life, Cmax, Tmax, AUC, Vd)
时间窗: 1 week
To evaluate the pharmacokinetics of repeated doses of CR845 in hemodialysis patients over a one-week treatment period.
次要结局
- Part B: Change in quality-of-life assessed using the Skindex-10 survey(2 weeks)
- Part B: Sleep disturbance assessed using Itch Medical Outcomes Study (MOS) survey(2 weeks)
研究者
研究点 (20)
Loading locations...
相似试验
终止
1 期
Insulin Tolerance Test Study in Patients With Type 1 DiabetesHypoglycemiaType 1 DiabetesNCT04026750High Point Clinical Trials Center5
已完成
2 期
A Study Evaluating Effects of Intranasal JNJ-17166864 on Symptoms of Allergic Rhinitis in AdultsAllergic RhinitisNCT00604123Johnson & Johnson Pharmaceutical Research & Development, L.L.C.74
已完成
2 期
A Study of Enzalutamide and LY3023414 in Men With Prostate CancerProstate Cancer MetastaticNCT02407054Eli Lilly and Company142
已完成
3 期
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)Rheumatoid ArthritisNCT02265705Eli Lilly and Company290
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671GoutHyperuricemiaNCT04060173Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.27